57 results about "Stroke treatment" patented technology

The present invention relates to methods for the diagnosis and evaluation of stroke and stroke sub-type. A variety of bio-markers are disclosed for assembling a panel for such diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects: the invention provides methods for early detection and differentiation of stroke subtypes, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for hemorrhagic transformation after thrombolyic therapy. Methods are disclosed that provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Methods for the diagnosis and evaluation of stroke and stroke sub-type employ a variety of bio-markers including cellular fibronectin (c-Fn) assembled as a panel for stoke diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects the methods permit early detection and differentiation of stroke subtypes, determination of the prognosis of a patient presenting stroke symptoms, and identification of a patient at risk for early hematoma growth and/or malignant massive cerebral artery infarction. The disclosed methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and to reduce the human and economic costs associated with incorrect stroke diagnosis.

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Methods and apparatus for assessing the condition of and treating patients for stroke during the delivery of continuous positive airway pressure (CPAP) are disclosed. By determining central and obstructive apnea occurrences or the percentile of pressure delivered to the patient from patient airflow, stroke indicators may be calculated and analyzed to provide information on the type of stroke a patient has suffered and the degree of a patient's neuro-recovery. The apparatus may be programmed with a particular protocol intended to identify between alternative forms of CPAP treatment appropriate for the patient based upon an assessment of the patient's condition. The device can select and recommend between the various treatment forms, identify billing reimbursement codes and generate data to track patient response to stroke treatments.

A system for treatment of ischemic stroke provides a stroke treatment workflow plan defining series of diagnostic actions and therapeutic actions to be performed at locations within a health care facility identified by beacons detectable by proximity sensors that travel with the patient. A first communications device having wireless communications capabilities receives a signal from a proximity sensor and typically transmits data to a second communications device having a visible timer and configured to receive data from and send data to other wireless communications devices. When the a patient undergoes diagnosis and treatment via the workflow plan, the system tracks the location of the patient within the workflow plan and the time at which the patient is at each location, and records the location of the patient and the time of the location within the workflow plan.

A method of post-stroke treatment at delayed timepoints with sigma receptor agonists. Sigma receptors are promising targets for neuroprotection following ischemia. One of the key components in the demise of neurons following ischemic injury is the disruption of intracellular calcium homeostasis. The sigma receptor agonist, DTG, was shown to depress [Ca²⁺]_i elevations observed in response to ischemia induced by sodium azide and glucose deprivation. Two sigma receptor antagonists, metaphit and BD-1047, were shown to blunt the ability of DTG to inhibit ischemia-evoked increases in [Ca²⁺]_i. DTG inhibition of ischemia-induced increases in [Ca²⁺]_i was mimicked by the sigma-1 receptor-selective agonists, carbetapentane, (+)-pentazocine and PRE-084, but not by the sigma-2 selective agonist, ibogaine, showing that activation of sigma-1 receptors is responsible for the effects. Activation of sigma receptors can ameliorate [Ca²⁺]_i dysregulation associated with ischemia in cortical neurons, providing neuroprotective properties. The effects of 1,3-di-o-tolyguanidine (DTG), a high affinity sigma receptor agonist, as a potential treatment for decreasing infarct area at delayed time points was further examined in rats. DTG treatment significantly reduced infarct area in both cortical/striatal and cortical/hippocampal regions by >80%, relative to control rats. These findings were confirmed by immunohistochemical experiments using the neuronal marker, mouse anti-neuronal nuclei monoclonal antibody (NeuN), which showed that application of DTG significantly increased the number of viable neurons in these regions. Furthermore, DTG blocked the inflammatory response evoked by MCAO, as indicated by decreases in the number of reactive astrocytes and activated microglia/macrophages detected by immunostaining for glial fibrillary acidic protein (GFAP) and binding of isolectin IB4, respectively. Thus, the sigma receptor-selective agonist, DTG, can enhance neuronal survival when administered 24 hr after an ischemic stroke. In addition, the efficacy of sigma receptors for stroke treatment at delayed time points is likely the result of combined neuroprotective and anti-inflammatory properties of these receptors.

The present invention provides methods of reducing mortality and morbidity associated with stroke. The GLP-1, GLP-1 analog or GLP-1 derivative is administered in a dose effective to normalize blood sugar.

The invention belongs to the field of medicines and provides application of a glycine-L-cysteine-L-phenylalanine tripeptide to preparation of medicines for treating stroke.According to animal experiments, by means of intravenous administration, the tripeptide penetrates blood brain barriers to enter brain tissues and cells so as to evidently reduce cerebral infarction volume of rats, and a stroke treatment function is realized.The glycine-L-cysteine-L-phenylalanine tripeptide available for conventional intravenous administration is functionally superior to existing clinical medicines.

The present invention provides a stroke treatment network system. The stroke treatment network system comprises a stroke screening system, a stroke big data center and an intelligent management center, and the stroke screening system is used for screening out stroke patients and obtaining corresponding clinical data; the stroke big data center is used for receiving the clinical data of the strokepatients, constructing a corresponding clinical biological sample library, and storing a pre-established intervention technology package library and a diagnosis and treatment scheme package library; and the intelligent management center is used for constructing a cerebral stroke risk prediction model in advance according to the clinical biological sample library to perform risk assessment on the clinical data, and pushing a pre-stored intervention technology package or diagnosis and treatment scheme package to a medical institution where the cerebral stroke patient is located according to an assessment result. The system constructs the corresponding clinical biological sample library, performs risk assessment on the stroke patients and pushes the corresponding intervention technology package and the diagnosis and treatment scheme package according to the assessment result, so that the conditions of the patients are intelligently analyzed, and treatment decision suggestions are providedfor doctors. The invention further provides an application method of the system.

The invention discloses a stroke treatment network system and a stroke treatment platform. A stroke treatment platform is constructed, the information expressway for acute stroke treatment is built before the hospital, so that seamless joint of pre-hospital first aid and in-hospital first aid, no arrival of a patient and first arrival of information are achieved, delay in the stroke hospital is reduced, acute stroke treatment time is gained, and thus the treatment efficiency of the acute stroke patient is improved. A three-in-one cerebral stroke treatment network integrating pre-hospital first aid, in-hospital diagnosis and treatment and post-hospital follow-up visit is built based on the stroke treatment platform, so that the pre-hospital stroke treatment process is standardized and unblocked, the treatment time is shortened, the treatment efficiency is improved, and the fatality rate and disability rate of stroke attack are practically reduced.

Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.

The invention relates to a traditional Chinese medicine for treating qi deficiency and blood stasis syndromes in the recovery period of ischemic stroke, and can effectively solve the medication problem of qi deficiency and blood stasis syndromes in the recovery period of ischemic stroke. The technical scheme adopted by the invention lies in that the traditional Chinese medicine is prepared from the following raw material medicines by weight: 9-18g of radix pseudostellariae, 30-60g of astragalus membranaceus, 12-21g of angelica sinensis, 18-30g of radix paeoniae rubra, 12-21g of salvia miltiorrhiza, 9-15g of zaocys dhumnade, 3-6g of ginger and 3-6g of jujubes. The traditional Chinese medicine is scientific and reasonable in compatibility, rich in raw materials, convenient to take and good in effects, has the effects of tonifying qi, activating blood circulation, dispersing blood stasis and dredging collaterals, can be effectively used for treating symptoms of ischemic stroke patients with qi deficiency and blood stasis syndromes in the recovery period, and is an innovation in stroke treatment medicine.

The invention relates to a stroke treatment instrument, which comprises an electromagnetic wave generator capable of applying electromagnetic waves to a patient. The waveform of the electromagnetic wave is shown in the specifications, 300 mu sec</=tau</=0.02 sec, 5 msec</=t1</=0.1 sec, tau is equal to a time constant generated by a generator in a driving circuit, t represents any time point, t1-t represents lasting time or working time of pulses, and Imax represents a maximum DC flowing through the circuit. The electromagnetic waves can effectively reduce clinical symptoms of the patient suffering from stroke.

The invention relates to a seven-insect compound traditional Chinese medicine for treating stroke, the problem of medication with a better stroke treatment effect can be effectively solved; the medicine comprises the following components: 88-94g of scorpion, 15.5 to 16.5 g of centipede, 15 to 16g of little multibanded krait, 72 to 79g of leech, 74 to 80g of ground beetle, 88 to 94g of earthworm, 88 to 94g of stiff silkworm, 130 to 155g of fruit of Chinese wolfberry, 130 to 155g of fructus alpiniae oxyphyllae, 130 to 155g of fructus broussonetiae, 110 to 130g of yam and 20 to 30g of liquorice.A method comprises the following steps: drying scorpion, centipede, little multibanded krait, leech, 1/2 weight of fructus alpiniae oxyphyllae and 1/2 weight of yam, and crushing into first fine powder; adding water to immerse the remaining medicines; performing decoction extraction for three times, and performing steps of filtration and filtrate concentration, spray drying, crushing to obtain second fine powder; mixing the first fine powder with the second fine powder, granulating, drying, granulating, and performing split packaging into capsules. The product is rich in raw materials, simplein preparation method, easy to prepare, convenient to take and good in effect, complies with the monarch, minister, assistant and guide formula principle, has the effects of relieving dizziness, dredging collaterals, promoting blood circulation, removing stasis, tonifying kidney and marrow, and is effectively used for various stroke hemiplegia, dysfunction, intelligent disorder, incontinence of defecation and the like.